— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation. — Q4 revenue was flat at $1.2 million, vs. $920,000 expected. — As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million. — Launch of […]
— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation. — Q4 revenue was flat at $1.2 million, vs. $920,000 expected. — As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million. — Launch of […]
— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation.
— Q4
revenue was flat at $1.2 million, vs. $920,000 expected.
— As
at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2
million.
— Launch
of Sixmo may be delayed due to the impact of Covid-19.
— TTNP
shares gained 4.4% during after-market trading hours.
